GenomeDx Biosciences seals multiple insurance deals for prostate cancer Dx

San Diego's GenomeDx Biosciences said it has sealed deals with three major insurers to cover the company's Decipher test, which measures a patient's risk of metastatic prostate cancer. Stratose, Three Rivers Provider Network and Fortified Provider Network--all PPOs--agreed to count the company and its test as a participating provider. Combined, the insurers cover more than 62.6 million people, the company said. GenomeDx, which launched in 2008, must still secure CMS coverage for the $4,250 test. Insurance reimbursement is the last major milestone diagnostics companies target when they launch new products. Item

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.